
noninferior to warfarin for the primary end point of stroke and systemic embolism (HR 0.79, 95% CI 0.66–0.96, P <0.001 for non inferiority). In the more-conventional and conservative intention-to-treat analysis, rivaroxa ban failed to achieve superiority (HR 0.88, 95% CI 0.74–1.03, P <0.001 for noninferiority, P = 0.12 for superiority), although a per-protocol, on-treatment analysis reported superiority for rivaro-xaban (HR 0.79, 95% CI 0.65–0.95, P = 0.02). The primary safety end point, major and non major clinically relevant bleeding, was not different (HR 1.03, 95% CI 0.96–1.11, P = 0.44), although hemorrhagic stroke, intracranial hemorrhage, and fatal-bleeding events were lower with rivaroxaban than warfarin.
Until the advent of novel oral anti-coagulants, patients with AF who were receiving oral anticoagulation often came under the care of a warfarin clinic, which was responsible for anticoagulation moni-toring and doses, rather than cardiologists per se. Now, clinicians will have to make informed decisions on doses of these novel drugs. Of the novel direct thrombin inhibi-tors, only dabigatran is approved for use for
stroke prevention in patients with AF, and this drug is licensed at doses of 110 mg or 150 mg twice daily (or 75 mg twice daily for patients with severe renal failure in the USA). Apart from the criteria of age (>80 years) and concomitant drug use (such as vera-pamil), how should the dose of dabigatran be decided on the basis of bleeding risk? To help clinical decision-making, a simple acronym of common risk factors for bleeding (the HAS-BLED score; Box 1) has been recom-mended in European and Canadian guide-lines. Various validations of the HAS-BLED score were published in 2011.4,5
In a large, contemporary, anti coagulated population of patients with AF, the HAS- BLED score performed best of all the tested bleeding-risk schemes, and more-accu-rately discriminated patients on the basis of their bleeding risk (whether assessed by the c- statistic, or estimates of Net Reclassification Improvement and Integrated Discrimination Improvement), with a step-wise increase in rates of major bleeding with increasing HAS-BLED score (P <0.0001 for trend).4 Multivariate analyses identified con-current aspirin use (HR 2.10), renal impair-ment (HR 1.98), age ≥75 years (HR 1.63), diabetes mellitus (HR 1.47), and heart failure or left ventricular dysfunction (HR 1.32) as significant predictors of bleeding.
What does this mean for clinicians in everyday practice, who have to balance the risks of stroke and bleeding? In a large, nationwide, ‘real-world’ cohort study from Denmark (n = 132,372), Olesen and col-leagues balanced stroke risk (assessed by the CHADS2 and CHA2DS2-VASc scores) with bleeding risk (assessed using the HAS-BLED score), and the net clinical benefit (Box 1) of ischemic-stroke preven-tion versus intracranial- hemorrhage risk
5
was calculated. The net clinical benefit was not positive for aspirin at any stroke-risk or bleeding-risk strata, which led the investi-gators to conclude that “aspirin should not be used for thromboprophylaxis in any patient with AF”.5 Unsurprisingly, the com-bination of warfarin plus aspirin did not confer any additional benefit in prevent-ing thromboembolism, but substantially increased bleeding risk.
In patients treated with warfarin, the only category where the net clinical benefit was negative was patients with a CHA2DS2-VASc score of 0, which reflects their truly low-risk status. The net clinical benefit was non- negative (either neutral or positive) at a CHADS2 score ≥0 and a CHA2DS2-VASc score ≥1. In addition, the net clinical benefit
was clearly positive, in favor of warfarin, in patients with increased risk of stroke or thromboembolism, and was even greater at high HAS-BLED scores (≥3), which indicates that patients at high risk of bleeding are also at high risk of stroke or thrombo embolism —and that the absolute benefit of warfarin in reducing the risk of ischemic stroke far outweighs the smaller absolute increase in the risk of serious bleeding. The practical use of the HAS-BLED score also encour-ages clinicians to consider bleeding risk factors that can be corrected, such as uncon-trolled blood pressure, concomitant use of aspirin or nonsteroidal anti- inflammatory drugs, and time in therapeutic range if the patient is on warfarin (the H, D, and L in HAS-BLED, respectively).
The year 2011 has seen great advances in assessment of stroke and bleeding risks in patients with AF, and exciting new data on the novel oral anticoagulants. Prospects are much improved for patients with AF.
University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Dudley Road, Birmingham B18 7QH, UK Competing interests
The author declares associations with the following companies and organizations: Astellas, AstraZeneca, Bayer, Biotronik, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi-Sankyo, focusAF, Merck,
Portola and Sanofi Aventis. See the article online for full details of the relationships.1.
Connolly, S. J. et al. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364, 806–817 (2011).
Granger, C. B. et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981–992 (2011).
Patel, M. R. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883–891 (2011).
Lip, G. Y., Frison, L., Halperin, J. L. & Lane, D. A. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol
Concomitantly) score. J. Am. Coll. Cardiol. 57, 173–180 (2011).
Olesen, J. B. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb. Haemost. 106, 739–749 (2011).
Ahrens, I., Lip, G. Y. & Peter, K. New oral
anticoagulant drugs in cardiovascular disease. Thromb. Haemost. 104, 49–60 (2010).
Karthikeyan, G. & Eikelboom, J. W. The CHADS2 score for stroke risk stratification in atrial fibrillation—friend or foe? Thromb. Haemost. 104, 45–48 (2010).
Lip, G. Y. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. J. Thromb. Haemost. 9 (Suppl. 1), 344–351 (2011).
2.
3.
4.
5.
6.
7.
8.

Stroke Prevention in Atrial Fibrillation -The ACTIVE Program Documented AF + ?1 risk factor: Age ?75, Hypertension, Prior stroke/TIA, LVEF<45, PAD, ...
Warfarin is the ?rst-line treatment for stroke prevention in patients with AF [1,2]. Biomarkers have been investigated for improving stroke prediction in...
非瓣膜性房颤抗凝治疗的大规模临床试验结果(AFASAK、SPAF、BAATAF、SPINAF、CAFA...SPAF(Stroke Prevention in Atrial Fibrillation Study) ? ? ? ? 入选:n=1330...
SPAF ( Stroke Prevention in AF )法华令明显优于 ASA 325mg/天,后者对非心源性卒中有效,对AF 卒中不明确推荐法华令适用于抗凝AF患者。ASA适用于年龄较轻,又不...
624-638 利于安慰剂 20 阿司匹林颅内出血荟萃分析与安慰剂相比,每千人每年仅增加0.3例颅内出血 PHS Preliminary report of the Stroke Prevention in Af Study ...
The first of these newer agents, dabigatran (Pradaxa, Boehringer Ingelheim), was recently approved for the prevention of stroke in patients with AF in ...
? For example, should both doses of dabigatran etexilate receive regulatory approval for stroke prevention in AF, dabigatran may be considered, as an ...
Eruo Heart Survey for AF 研究对 1084 例真实世界中房颤患者的血栓风险分别... al. Warfarin versus aspirin for stroke et prevention in an elderly ...
stroke prevention for patients with atrial fibrillation 达比加群酯与华法林的...合并卒中高危因素的AF患者随机、双盲 阿哌沙班 5mg po bid 华法林 目标INR2-...
(30 血栓栓塞性并发症血栓栓塞性并发症-脑卒中 房颤分类初发 AF 首次发现,不...stroke prevention for patients with atrial fibrillation 达比加群酯与华法林的...
热门文档